Insulet Earnings: Here’s Why Investors are Not Happy Now
Insulet Corporation (NASDAQ:PODD) had a loss and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 0.87%.
Insulet Corporation Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.21 in the quarter versus EPS of $-0.30 in the year-earlier quarter.
Revenue: Rose 22.48% to $57.8 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Insulet Corporation reported adjusted EPS loss of $0.21 per share. By that measure, the company beat the mean analyst estimate of $-0.22. It missed the average revenue estimate of $59.02 million.
Quoting Management: “2012 was an extremely successful year across all fronts for Insulet, with strong revenue growth and expanded gross margins driving us to operating cash profitability in the fourth quarter,” said Duane DeSisto, President and Chief Executive Officer of Insulet. “The year culminated with our most exciting accomplishment, FDA clearance of the new OmniPod. We have begun shipping the new OmniPod to new customers and expect to begin transitioning our existing customer base to the new OmniPod in the coming weeks. Looking ahead to 2013, we expect continued growth to be driven by robust demand for the new OmniPod, which retains all the easy-to-use features of the original OmniPod, and is over a third smaller in size and a quarter lighter.”
Key Stats (on next page)…